

## DAFTAR PUSTAKA

- Abubakari, A., Issah, H., Mutaka, M.A.O., dan Asumah, M.N., 2023. Determinants of Virological Failure in HIV Patients on Highly Active Antiretroviral Therapy (HAART): A Retrospective Cross-Sectional Study in the Upper East Region of Ghana. *Venereology*, **2**: 16–29.
- Anoje, C., Agu, K.A., Oladele, E.A., Badru, T., Adedokun, O., Oqua, D., dkk., 2017. Adherence to On-Time ART Drug Pick-Up and Its Association with CD4 Changes and Clinical Outcomes Amongst HIV Infected Adults on First-Line Antiretroviral Therapy in Nigerian Hospitals. *AIDS and Behavior*, **21**: 386–392.
- Anwar, K.P., Malik, A., dan Subhan, K.H., 2012. Profile of candidiasis in HIV infected patients. *Iranian Journal of Microbiology*, **4**: 204–209.
- Anwar, Y., Nugroho, S.A., dan Wulandari, S.D., 2018. Profile Of Antiretroviral Side Effects On Hiv In Rspi Prof. Dr. Sulianti Saroso Jakarta. *JURNAL ILMU KEFARMASIAN INDONESIA*, **16**: 49–55.
- Aquaro, S., Borrajo, A., Pellegrino, M., dan Svicher, V., 2020. Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages. *Virulence*, **11**: 400–413.
- Arisudhana, G.A.B., Sofro, M.A.U., dan Sujianto, U., 2018. Antiretroviral Side Effects on Adherence in People Living with HIV/AIDS. *Nurse Media Journal of Nursing*, **8**: 79–85.
- Balakrishnan, P., Iqbal, H.S., Shanmugham, S., Mohanakrishnan, J., Solomon, S.S., Mayer, K.H., dkk., 2011. Low-cost assays for monitoring HIV infected individuals in resource-limited settings. *The Indian Journal of Medical Research*, **134**: 823–834.
- Bogale, B., Asefa, A., Destaw, A., Midaksa, G., Asaye, Z., Alemu Gebremichael, M., dkk., 2022. Determinants of virological failure among patients on first line highly active antiretroviral therapy (HAART) in Southwest Ethiopia: A case-control study. *Frontiers in Public Health*, **10**: 1-9
- Castellino, S., Moss, L., Wagner, D., Borland, J., Song, I., Chen, S., dkk., 2013. Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans. *Antimicrobial Agents and Chemotherapy*, **57**: 3536–3546.
- CDC, 2022a. 'HIV Testing | HIV/AIDS | CDC', URL: <https://www.cdc.gov/hiv/testing/index.html> (diakses tanggal 27/9/2022).
- CDC, 2022b. 'Opportunistic Infections | Living with HIV | HIV Basics | HIV/AIDS | CDC', URL: <https://www.cdc.gov/hiv/basics/livingwithhiv/opportunisticinfections.html> (diakses tanggal 17/9/2022).
- Damayanti, N., 2020. Analysis of First-Line Antiretroviral Therapy toward Patients with HIV/AIDS in Indonesia. *J. Pharm. Sci.*, **12**:730-733
- Desta, A.A., Kidane, K.M., Bahta, Y.W., Ajemu, K.F., Woldegebriel, A.G., Berhe, A.A., dkk., 2020. Determinants of immunological recovery following

- HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study. *BMJ Open*, **10**: e038741.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2017. *Buku saku Program Pengendalian HIV AIDS dan PIMS di Fasilitas Kesehatan Tingkat Pertama*, 3. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2020a. *Surat Edaran Nomor PM.02.04/III/2919/2020 Tentang Rekomendasi Optimalisasi Penyempurnaan Paduan Obat Regimen Antiretroviral (ARV)*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2020b. *Laporan Perkembangan HIV/AIDS, PIMS Triwulan IV Tahun 2019*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2022a. *Laporan Perkembangan Kasus AIDS Dan PIMS Triwulan IV Tahun 2021*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2022b. *Laporan Perkembangan Kasus AIDS Dan PIMS Triwulan III Tahun 2022*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Dwi Puspitasari, W., Yasin, N., dan Rahmawati, F., 2018. Comparison of Treatment Outcomes among Second-Line Antiretroviral Regimens in HIV/AIDS Patient. *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, **8**: 119.
- Eggleton, J.S. dan Nagalli, S., 2022. Highly Active Antiretroviral Therapy (HAART), dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Fite, M.B., Aga, D.J., dan Gemed, H.F., 2022. Determinants of Opportunistic Disease among Patients Attending ART Clinic, in Western Oromia, Ethiopia. *Virology & Mycology*, **11**: 1–7.
- Fitrianingsih, F., Ersas, C.B., Indriyani, D., dan Wirdayanti, W., 2022. GAMBARAN KARAKTERISTIK PASIEN HIV DI POLI RAWAT JALAN RSUD RADEN MATTABER JAMBI. *Jurnal Ilmiah Ilmu Terapan Universitas Jambi/JIITUJ*, **6**: 164–172.
- Hailu, G.G., Hagos, D.G., Hagos, A.K., Wasihun, A.G., dan Dejene, T.A., 2018. Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia. *PloS One*, **13**: e0196259.
- Haryati, M.R., Asmarawati, T.P., dan Hadi, U., 2019. Informasi Dasar HIV/AIDS, dalam: *Manajemen HIV/AIDS: Terkini, Komprehensif, Dan Multidisiplin*. Airlangga University Press, Surabaya, hal. 3–21.
- Hoffmann, C., Welz, T., Sabranski, M., Kolb, M., Wolf, E., Stellbrink, H.-J., dkk., 2017. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. *HIV medicine*, **18**: 56–63.
- Juhaefah, A.J.A., 2020. GAMBARAN KARAKTERISTIK PASIEN HIV/AIDS YANG MENDAPAT ANTIRETROVIRAL THERAPY (ART). *Jurnal Medika : Karya Ilmiah Kesehatan*, **5**: .

- Justiz-Vaillant, A.A. dan Gulick, P.G., 2022. HIV Disease Current Practice, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Kambu, Y., Waluyo, A., dan Kuntarti, K., 2016. Umur Orang dengan HIV AIDS (ODHA) Berhubungan dengan Tindakan Pencegahan Penularan HIV. *Jurnal Keperawatan Indonesia*, **19**: 200–207.
- Kandel, C.E. dan Walmsley, S.L., 2015. Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV. *Drug Design, Development and Therapy*, **9**: 3547–3555.
- Kanters, S., Vitoria, M., Zoratti, M., Doherty, M., Penazzato, M., Rangaraj, A., dkk., 2020. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. *EClinicalMedicine*, **28**: 100573.
- Kelley, C.F., Kitchen, C.M.R., Hunt, P.W., Rodriguez, B., Hecht, F.M., Kitahata, M., dkk., 2009. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **48**: 787–794.
- Kementerian Kesehatan RI, 2015. *Peraturan Menteri Kesehatan Nomor 87 Tahun 2015 tentang Pedoman Pengobatan Antiretroviral*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan RI, 2019. *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/90/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan RI, 2020. *Infodatin Pusat Data Dan Informasi Kementerian Kesehatan RI*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kemnic, T.R. dan Gulick, P.G., 2022. HIV Antiretroviral Therapy, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Kishore, A. dan M N, S., 2015. ASSASYING THE NEED OF COMMERCIAL PLASMA VIRAL LOAD TESTING IN RESOURCE LIMITED SETTINGS. *Journal of Evolution of Medical and Dental Sciences*, **4**: 13122–13134.
- Kolakowska, A., Maresca, A.F., Collins, I.J., dan Cailhol, J., 2019. Update on Adverse Effects of HIV Integrase Inhibitors. *Current Treatment Options in Infectious Diseases*, **11**: 372–387.
- Lemeshow, S., Hosmer Jr., D.W., Klar, J., dan Lwanga, S.K., 1997. *Besar sampel dalam penelitian kesehatan*. Gadjah Mada University Press, Yogyakarta.
- Li, G. dan De Clercq, E., 2016. HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. *Microbiology and Molecular Biology Reviews* : *MMBR*, **80**: 679–731.
- Lockman, S., Brummel, S.S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., dkk., 2021. Efficacy and safety of dolutegravir- and tenofovir alafenamide fumarate-containing HIV antiretroviral treatment regimens

- started in pregnancy: a randomised controlled trial. *Lancet (London, England)*, **397**: 1276–1292.
- Maartens, G., Celum, C., dan Lewin, S.R., 2014. HIV infection: epidemiology, pathogenesis, treatment, and prevention. *Lancet (London, England)*, **384**: 258–271.
- Malani, P.N., 2016. Human Immunodeficiency Virus. *JAMA*, **316**: 238.
- Manuaba, I.A.K.W. dan Yasa, I.W.P.S., 2017. TINGKAT KEPATUHAN MENGKONSUMSI OBAT ANTIRETROVIRAL DENGAN JUMLAH CD4 PADA PASIEN HIV AIDS DI KLINIK VCT RSUP SANGLAH DALAM PERIODE SEPTEMBER – NOVEMBER 2014. *E-Jurnal Medika Udayana*, **6**: .
- Maqutu, D., Zewotir, T., North, D., Naidoo, K., dan Grobler, A., 2010. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. *African journal of AIDS research : AJAR*, **9**: 117–124.
- Meireles, M.V., Pascom, A.R.P., Duarte, E.C., dan McFarland, W., 2019. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. *AIDS*, **33**: 1663–1668.
- Meshesha, H.M., Nigussie, Z.M., Asrat, A., dan Mulatu, K., 2020. Determinants of virological failure among adults on first-line highly active antiretroviral therapy at public health facilities in Kombolcha town, Northeast, Ethiopia: a case–control study. *BMJ Open*, **10**: e036223.
- Mulyantari, K., Retnowati, E., dan Nasronudin, N., 2016. INTERLEUKIN-10 PLASMA DAN LIMFOSIT-T CD4+ PENDERITA TERINFEKSI HIV. *INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY*, **18**: 20–29.
- Nachega, J.B., Hislop, M., Nguyen, H., Dowdy, D.W., Chaisson, R.E., Regensberg, L., dkk., 2009. Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa. *Journal of acquired immune deficiency syndromes (1999)*, **51**: 65–71.
- Nickel, K., Halfpenny, N.J.A., Snedecor, S.J., dan Puneekar, Y.S., 2021. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. *BMC Infectious Diseases*, **21**: 222.
- Patel, D.A., Snedecor, S.J., Tang, W.Y., Sudharshan, L., Lim, J.W., Cuffe, R., dkk., 2014. 48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis. *PLOS ONE*, **9**: e105653.
- Puspasari, D., Wisaksana, R., dan Rovina, R., 2018. Gambaran Efek Samping dan Kepatuhan Terapi Antiretroviral pada Pasien HIV di Rumah Sakit Dr. Hasan Sadikin Bandung tahun 2015. *Jurnal Sistem Kesehatan*, **3**: 175–181.
- Rajesh, R., Sudha, V., Varma, D., dan Sonika, S., 2012. Association between Medication Adherence Outcomes and Adverse Drug Reactions to Highly

- Active Antiretroviral Therapy in Indian Human Immunodeficiency Virus-Positive Patients. *Journal of Young Pharmacists : JYP*, **4**: 250–260.
- Saktina, P.U. dan Satriyasa, B.K., 2017. KARAKTERISTIK PENDERITA AIDS DAN INFEKSI OPORTUNISTIK DI RUMAH SAKIT UMUM PUSAT SANGLAH DENPASAR PERIODE JULI 2013 SAMPAI JUNI 2014. *E-Jurnal Medika Udayana*, **6**: 1–6.
- Sigalingging, N., Sitorus, R.J., dan Flora, R., 2022. Determinants of Adherence to Antiretroviral Therapy in HIV/AIDS Patients in Jambi. *Media Kesehatan Masyarakat*, **4**: 273–283.
- Stellbrink, H.-J., Reynes, J., Lazzarin, A., Voronin, E., Pulido, F., Felizarta, F., dkk., 2013. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. *AIDS (London, England)*, **27**: 1771–1778.
- The NAMSAL ANRS 12313 Study Group, 2019. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. *New England Journal of Medicine*, **381**: 816–826.
- UNAIDS, 2022. 'Global HIV & AIDS statistics — Fact sheet', URL: <https://www.unaids.org/en/resources/fact-sheet> (diakses tanggal 30/9/2022).
- Venter, W.D.F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., dkk., 2019. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. *New England Journal of Medicine*, **381**: 803–815.
- Walmsley, S.L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., dkk., 2013. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. *New England Journal of Medicine*, **369**: 1807–1818.
- Waymack, J.R. dan Sundareshan, V., 2022. Acquired Immune Deficiency Syndrome, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Weller, S., Borland, J., Chen, S., Johnson, M., Savina, P., Wynne, B., dkk., 2014. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. *European Journal of Clinical Pharmacology*, **70**: 29–35.
- World Health Organization, 2016. WHO clinical staging of HIV disease in adults, adolescents and children, dalam: *Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd Edition*. World Health Organization.
- World Health Organization, 2019a. 'Policy brief: update of recommendations on first- and second-line antiretroviral regimens', World Health Organization.
- World Health Organization, 2019b. *HIV Molecular Diagnostics Toolkit to Improve Access to Viral Load Testing and Infant Diagnosis*. World Health Organization.
- World Health Organization, 2021. *SUMMARY RECOMMENDATIONS, Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach* [Internet]. World Health Organization.
- World Health Organization, 2022. 'HIV/AIDS', URL: <https://www.who.int/health-topics/hiv-aids> (diakses tanggal 19/9/2022).



- Wu, K., 2019. 'Dolutegravir vs. Efavirenz in HIV-Treatment Regimens | NEJM Resident 360', *mms.org*. URL: <https://resident360.nejm.org/from-pages-to-practice/dolutegravir-vs-efavirenz-in-hiv-treatment-regimens> (diakses tanggal 22/9/2022).
- Yogani, I., Karyadi, T.H., Uyainah, A., dan Koesnoe, S., 2015. Faktor-faktor yang Berhubungan dengan Kenaikan CD4 pada Pasien HIV yang Mendapat Highly Active Antiretroviral Therapy dalam 6 bulan Pertama. *Jurnal Penyakit Dalam Indonesia*, **2**: 217–222.
- Yu, Y., Luo, D., Chen, X., Huang, Z., Wang, M., dan Xiao, S., 2018. Medication adherence to antiretroviral therapy among newly treated people living with HIV. *BMC Public Health*, **18**: 825.
- Zhong, M., Li, M., Qi, M., Su, Y., Yu, N., Lv, R., dkk., 2023. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China. *Frontiers in Immunology*, **13**: 1033098.